Methods Study to Characterize Early Indicators of Weight Loss in People

Back to Search
Print
Bookmark Trial

NCT00383253

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Adelaide, South Australia, 5000, Australia
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Obesity
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-55 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects >=18 years of age with BMI >= 30 and < 40 kg/m2

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Females, those with illnesses expected to cause weight loss, those without stable body
weight within 3 months of screening.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

ObesityPharmacokinetics Of Tigecycline In Morbidly Obese Subjects
NCT01560143
  1. Albany, New York
ALL GENDERS
18 Years+
years
MULTIPLE SITES
ObesityRandomized, Controlled, Open, Comparative Intervention Study for Obesity Prevention in Children
NCT00438555
  1. Petach Tikva,
ALL GENDERS
5 Years+
years
MULTIPLE SITES
ObesitySafety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight Adults
NCT00331175
  1. New Haven, Connecticut
ALL GENDERS
18 Years+
years
MULTIPLE SITES
ObesityA 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients
NCT00391196
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Huntsville, Alabama
  4. Mobile, Alabama
  5. Chandler, Arizona
  6. Mesa, Arizona
  7. Phoenix, Arizona
  8. Fresno, California
  9. Palm Springs, California
  10. Tustin, California
  11. Walnut Creek, California
  12. New Britain, Connecticut
  13. Washington, District of Columbia
  14. Orlando, Florida
  15. West Palm Beach, Florida
  16. Honolulu, Hawaii
  17. Gurnee, Illinois
  18. Madisonville, Kentucky
  19. Baton Rouge, Louisiana
  20. Metairie, Louisiana
  21. Auburn, Maine
  22. Scarborough, Maine
  23. Baltimore, Maryland
  24. Bay City, Michigan
  25. Troy, Michigan
  26. Edina, Minnesota
  27. Jefferson City, Missouri
  28. Albuquerque, New Mexico
  29. Buffalo, New York
  30. New York, New York
  31. Greenville, North Carolina
  32. Beaver, Pennsylvania
  33. Cumberland, Rhode Island
  34. Pawtucket, Rhode Island
  35. Greer, South Carolina
  36. Bristol, Tennessee
  37. Nashville, Tennessee
  38. Dallas, Texas
  39. Dallas, Texas
  40. San Antonio, Texas
  41. San Antonio, Texas
  42. Renton, Washington
  43. Morgantown, West Virginia
  44. Buenos Aires,
  45. Buenos Aires,
  46. Buenos Aires,
  47. Garran, Australian Capital Territory
  48. Wollongong, New South Wales
  49. Adelaide, South Australia
  50. Box Hill, Victoria
  51. Nedlands, Western Australia
  52. Curitiba, PR
  53. Porto Alegre, RS
  54. São Paulo, SP
  55. São Paulo, SP
  56. São Paulo, SP
  57. São Paulo, SP
  58. Red Deer, Alberta
  59. Coquitlam, British Columbia
  60. Winnipeg, Manitoba
  61. Thornhill, Ontario
  62. Charlottetown, Prince Edward Island
  63. L'Ancienne-Lorette, Quebec
  64. Saint-Marc-des-Carrières, Quebec
  65. Breclav,
  66. Ceske Budejovice,
  67. Olomouc,
  68. Praha 2,
  69. Praha 4 - Krc,
  70. Berlin,
  71. Dresden,
  72. Duesseldorf,
  73. Hamburg,
  74. Leipzig,
  75. Mittweida,
  76. Tampico, Cd. Madero
  77. Mexico, DF
  78. Guadalajara, Jalisco
  79. Monterrey, Nuevo León
  80. Banska Bystrica,
  81. Bratislava,
  82. Lubochna,
  83. Nitra,
  84. Goteborg,
  85. Huddinge,
  86. Edinburgh, Lothian
  87. Bath, Somerset
  88. Coventry,
  89. Dumfries,
  90. Dundee,
  91. Luton,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Methods Study to Characterize Early Indicators of Weight Loss in People
Official Title  ICMJE A Randomized, Open-Label, Parallel Group, Fixed Energy Deficit Methodology Trial to Characterize Early Efficacy Biomarkers During Treatment of Obesity in Adult, Obese, Male Subjects.
Brief Summary Methods study to characterize early indicators of weight loss in people.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Obesity
Intervention  ICMJE
  • Behavioral: caloric restriction - 10%
    Subjects maintained on 10% caloric restriction (caloric intake = 90% of baseline)
  • Behavioral: caloric restriction - 25%
    Subjects maintained on 25% caloric restriction (caloric intake = 75% of baseline)
  • Behavioral: caloric restriction - 50%
    Subjects maintained on 50% caloric restriction (caloric intake = 50% of baseline)
  • Behavioral: caloric restriction - Control
    Subjects maintained on their baseline caloric intake (caloric restriction = none)
Study Arms  ICMJE
  • Experimental: 10%
    Intervention: Behavioral: caloric restriction - 10%
  • Experimental: 25%
    Intervention: Behavioral: caloric restriction - 25%
  • Experimental: 50%
    Intervention: Behavioral: caloric restriction - 50%
  • Placebo Comparator: Control
    Intervention: Behavioral: caloric restriction - Control
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: March 20, 2009)		57
Original Enrollment  ICMJE
 (submitted: October 2, 2006)		48
Actual Study Completion Date  ICMJE March 2008
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Subjects >=18 years of age with BMI >= 30 and < 40 kg/m2

Exclusion Criteria:

  • Females, those with illnesses expected to cause weight loss, those without stable body weight within 3 months of screening.
Sex/Gender  ICMJE
Sexes Eligible for Study:Male
Ages  ICMJE 18 Years to 55 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00383253
Other Study ID Numbers  ICMJE A9001342
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE
  • University of Adelaide
  • Royal Adelaide Hospital
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date March 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP